



Lower risk of prostate cancer and related mortality in those who are treated with TUMT compared to TURP.

Today, at the Swedish “Urologidagarna 2022” in Malmö, Dr Fredrik Stenmark presented results from a registry study evaluating the risk of prostate cancer and prostate cancer-specific mortality for patients with BPH treated with thermotherapy (TUMT) or surgery (TURP). Older men with benign prostatic hyperplasia may have a significantly lower risk of developing both prostate cancer and prostate cancer-specific mortality if they are treated with TUMT compared with TURP.

A research group consisting of Professor Daniel Altman, Professor Jan-Erik Damber, Professor Anders Bjartell together with the PhD urologists Dr Caroline Elmér, Dr Björn Zackrisson, Dr Sonny Schelin and Dr Fredrik Stenmark has conducted a national registry study and concludes that among elderly men with BPH, TUMT may decrease the risk of prostate cancer and related death compared to TURP. The research group's study results show that there are significantly higher risks with TURP compared to TUMT both in terms of prostate cancer diagnosis and prostate cancer-specific mortality. TUMT stands for TransUrethral Microwave Therapy and is the medical name for the basic methodology in ProstaLund's further developed treatment method CoreTherm® Concept. TURP stands for TransUrethral Resection of the Prostate.

In ProstaLund's previously communicated registry data from 2021, just over 8% of all those who had surgery with TURP received prostate cancer diagnosis within 30 days and in this group the prostate cancer-specific mortality was at its highest. Stenmark today also referred to a recently published Danish register study (Hilscher et al, 2022) where the results were in line with ProstaLund's register data. 16% of the approximately 50,000 Danish patients who had surgery with TURP were diagnosed with prostate cancer when the tissue sample was analyzed. And the prostate cancer-specific mortality rate for all those who had TURP surgery in that study was 14%.

The design of the Swedish research group's new study differs somewhat from the register data that ProstaLund communicated a year and a half ago. The new study has used the National Board of Health and Welfare's diagnose register, procedure register, cause of death register and cancer register as sources. All men who have undergone either TURP or TUMT from January 1, 1999 to December 31, 2019 in Sweden are included in the new study. The research group has also *excluded all patients who have been diagnosed with prostate cancer within one year from action.*



PRESS RELEASE
07 October 2022 11:31:00 CEST

Despite this scientifically motivated study design to avoid bias, the risk of both diagnosis and mortality from prostate cancer is lower after TUMT than after TURP according to the data that Stenmark presented today. – 4.6% (216 out of 4,686) of those treated with TUMT and 6.1% (4,574 of 74,527) of those treated with TURP have received a prostate cancer diagnosis during the follow-up period. In terms of prostate cancer-specific mortality, there was an even greater difference between the groups, 59 (1.2%) for TUMT-treated and 1,653 (2.2%) for those who had TURP performed.

"Given our own previous registry data, it is far from surprising that the professors and PhD urologists arrive at this result. We already have data that CoreTherm has the same efficacy and fewer serious complications compared to TURP and now we can also add lower risk of prostate cancer and prostate cancer-specific mortality in the aftermath. If I was a patient receiving this information I would choose our method.", comments CEO Johan Wennerholm.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-10-07 11:31 CEST.

Attachments

Lower risk of prostate cancer and related mortality in those who are treated with TUMT compared to TURP.